Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol.

Kristine Yaffe1,2, Deborah E Barnes1,2, Dori Rosenberg3

  • 1University of California, San Francisco, San Francisco, CA, USA.

Journal of Alzheimer'S Disease : JAD
|November 27, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
This summary is machine-generated.

This pilot trial tests a personalized intervention to reduce Alzheimer's disease (AD) risk factors in older adults. The Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT) aims to improve cognitive function and health outcomes.

Area of Science:

  • Gerontology
  • Neurology
  • Public Health

Background:

  • Alzheimer's disease (AD) poses a significant public health challenge, with growing evidence linking modifiable risk factors to its development.
  • Early intervention targeting multiple risk factors may offer a promising strategy for AD risk reduction.
  • A personalized, pragmatic approach within an integrated healthcare system is needed to test such interventions.

Purpose of the Study:

  • To describe the protocol for the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT), a pilot randomized trial.
  • To evaluate a personalized, multi-domain intervention aimed at reducing Alzheimer's disease risk in higher-risk older adults.
  • To assess the intervention's impact on cognitive change and various modifiable risk factors over two years.

Main Methods:

Keywords:
Alzheimer’s diseasedementiahealth promotionintegrated delivery of health carerisk reduction behavior

Related Experiment Videos

  • A single-blind, randomized pilot trial involving 200 higher-risk older adults (aged 70-89) with cognitive complaints.
  • Participants are randomized to either the SMARRT intervention (personalized coaching for risk factors) or a Health Education (HE) control group.
  • Randomization is stratified by clinic, race/ethnicity, and age. Outcomes are assessed over 24 months.

Main Results:

  • The primary outcome is the two-year change in a cognitive test composite score.
  • Secondary outcomes include improvements in targeted risk factors, individual cognitive domains, physical performance, functional ability, quality of life, and incidence of mild cognitive impairment, AD, and dementia.
  • Data collection occurs at baseline and at 6, 12, 18, and 24 months.

Conclusions:

  • The SMARRT protocol outlines a rigorous approach to testing a novel, personalized intervention for Alzheimer's disease risk reduction.
  • This pilot trial will provide crucial data on the feasibility, effectiveness, and potential impact of multi-domain interventions in a real-world healthcare setting.
  • Findings will inform future, larger-scale trials aimed at preventing or delaying Alzheimer's disease onset.